NCT01979679View on ClinicalTrials.gov

A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone

PHASE3CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

October 31, 2013

Conditions
Schizophrenia
Interventions
DRUG

Lurasidone 80 mg

DRUG

Lurasidone 120 mg

DRUG

Lurasidone 160 mg

Trial Locations (1)

92868

UCI Medical Center, Orange

Sponsors
All Listed Sponsors
collaborator

Dainippon Sumitomo Pharma America

INDUSTRY

lead

University of California, Irvine

OTHER